Source: Eur Respir J 2006; 27: 483-494
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jayaram L., Pizzichini M. M., Cook R. J., Boulet L-P., Lemiere C., Pizzichini E., Cartier A., Hussack P., Goldsmith C. H., Laviolette M., Parameswaran K., Hargreave F. E.. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-494

Member's Comments

No comment yet.

Related content which might interest you: The use of sputum differential cell counts and soluble phase measurements to assess airway inflammation in children with asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002 Sputum cell counts and exacerbations of airway diseases Source: Eur Respir J 2005; 26: Suppl. 49, 485s Year: 2005 Induced sputum and blood T lymphocyte activation during exacerbations of severe asthmatics: the ISEA study Source: Annual Congress 2006 - Towards understanding the pathogenesis of asthma Year: 2006 Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016 Sputum induction in severe exacerbations of asthma: safety of a modified method Source: Eur Respir J 2011; 38: 979-980 Year: 2011 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Impact on steroid dosing after introducing sputum eosinophils count into a severe asthma clinic Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity Year: 2008 Bacterial exacerbation of COPD: assessment of neutrophil activation in induced sputum Source: Annual Congress 2004 - Role of infection in COPD Year: 2004 Changes in the induced sputum proteome during COPD exacerbations Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020 Does the infection influence on induced sputum cell count at smokers and nonsmokers with COPD exacerbation? Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005 Infection influence on induced sputum cell count at smokers and nonsmokers with COPD exacerbation Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 Role of sputum eosinophil levels in the assessment of asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004 LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Comparative characteristics of induced sputum and brush-biopsy cell counts in COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 299s Year: 2005 Relationship of blood eosinophil count to exacerbations in COPD Source: International Congress 2016 – Airway response to infection Year: 2016 Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016